Broadcast Date: March 20, 2024
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Pancreatic cancer is a complex disease with few treatment options and poor prognosis, in part due to the dearth of suitable models for studying its progression and assessing patients’ response to therapy. Interest in patient-derived organoids for the treatment of pancreatic cancer is growing because organoids better recapitulate the complexity and population diversity of patients as compared to more traditionally used cell lines. A major hurdle to executing these models is the challenging method used to culture organoids which often consists of maintaining organoids in domes of extracellular matrices (ECMs). These ECMs are viscous and temperature sensitive which can present challenges when used in conjunction with automated liquid handling systems.
In this GEN Learning Lab, our speakers will discuss an alternative technique for maintaining organoids in Corning® Elplasia® microplates using media supplemented with Corning Matrigel® matrix. During the event, you’ll learn about applications of patient-derived organoids to pancreatic cancer cases including examples that showcase the value of using these models to assess patients’ responses to treatment. You’ll also hear examples of how organoids’ predictive power is robust and consistent across passage, different sources and lots of basement membrane extract.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Senior Scientist
Corning Life Sciences
Assistant Professor
Helen McLoraine Developmental Chair
Salk Institute
Learning Lab produced with support from:
